Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease

Neurochemical Research

Volumn 28, Issue 7, 2003, Pages 1009-1015

  Sant'Angelo, Antonino ^a,b   Trinchese, Fabrizio ^a,b   Arancio, Ottavio ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer's disease; Behavior; Electrophysiology; Learning; Long term potentiation

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; BEHAVIOR; BRAIN ELECTROPHYSIOLOGY; COGNITION; DRUG DESIGN; LEARNING; LONG TERM POTENTIATION; MAZE TEST; NERVE CELL PLASTICITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; TASK PERFORMANCE; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BEHAVIOR, ANIMAL; ELECTROPHYSIOLOGY; MEMORY DISORDERS;

ANIMALIA;

EID: 0037955990     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023251005197     Document Type: Review

References (56)

1. Price, D. L. and Sisodia, S. S. 1998. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479-505.
2. Duff, K. 1994. Modeling Alzheimer's disease in transgenic mice. J. Fla. Med. Assoc. 81:625-628.
3. Price, D. L., Sisodia, S. S., and Borchelt, D. R. 1998. Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282:1079-1083.
4. Lee, M. K., Borchelt, D. R., Wong, P. C., Sisodia, S. S., and Price, D. L. 1996. Transgenic models of neurodegenerative diseases. Curr. Opin. Neurobiol. 6:651-660.
5. Bolivar, V., Cook, M., and Flaherty, L. 2000. List of transgenic and knockout mice: behavioral profiles. Mamm. Genome 11:260-274.
6. Duff, K. 1997. Alzheimer transgenic mouse models come of age. Trends Neurosci. 20:279-280.
7. Higgins, L. S. and Cordell, B. 1995. Transgenic mice and modeling Alzheimer's disease. Rev. Neurosci. 6:87-96.
8. Duff, K. 1998. Recent work on Alzheimer's disease transgenics. Curr. Opin. Biotechnol. 9:561-564.
9. Sirinathsinghji, D. J. 1998. Transgenic mouse models of Alzheimer's disease. Biochem. Soc. Trans. 26:504-508.
10. Janus, C., Chishti, M. A., and Westaway, D. 2000. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta. 1502:63-75.
11. Aguzzi, A., Brandner, S., Marino, S., and Steinbach, J. P. 1996. Transgenic and knockout mice in the study of neurodegenerative diseases. J. Mol. Med. 74:111-126.
12. Hock, B. J., Jr. and Lamb, B. T. 2001. Transgenic mouse models of Alzheimer's disease. Trends Genet. 17:S7-S12.
13. Khachaturian, Z. S. 1985. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1097-1105.
14. Hsiao, K. K., Borchelt, D. R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., Younkin, S., and Price, D. 1995. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15:1203-1218.
15. Lipp, H. P. and Wolfer, D. P. 1998. Genetically modified mice and cognition. Curr. Opin. Neurobiol. 8:272-280.
16. Wehner, J. M., Bowers, B. J., and Paylor, R. 1996. The use of null mutant mice to study complex learning and memory processes. Behav. Genet. 26:301-312.
17. Picciotto, M. R. and Wickman, K. 1998. Using knockout and transgenic mice to study neurophysiology and behavior. Physiol. Rev. 78:1131-1163.
18. Crawley, J. N., Belknap, J. K., Collins, A., Crabbe, J. C., Frankel, W., Henderson, N., Hitzemann, R. J., Maxson, S. C., Miner, L. L., Silva, A. J., Wehner, J. M., Wynshaw-Boris, A., and Paylor, R. 1997. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132:107-124.
19. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
20. Moran, P. M., Higgins, L. S., Cordell, B., and Moser, P. C. 1995. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA 92:5341-5345.
21. Wolfer, D. P., Muller, U., Stagliar, M., and Lipp, H. P. 1997. Assessing the effects of the 129/Sv genetic background on swimming navigation learning in transgenic mutants: a study using mice with a modified beta-amyloid precursor protein gene. Brain Res. 771:1-13.
22. Silva, A. J., Simpson, E. M., Takahashi, J. S., Lipp, H. P., Nakanishi, S., Wehner, J. M., Giese, K. P., Tully, T., Abel, T., Chapman, P. F., Fox, K., Grant, S., Shigeyoshi, I., Lathe, R., Mayford, M., McNamara, J. O., Morris, R. J., Picciotto, M., Roder, J., Shin, H. S., Slesinger, P. A., Storm, D. R., Stryker, M. P., Tonegawa, S., Wang, Y., and Wolfer, D. P. 1997. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 19:755-759.
23. Crabbe, J. C., Wahlstenm, D., and Dudek, B. C. 1999. Genetics of mouse behavior: interactions with laboratory environment. Science 284:1670-1672.
24. Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., and Fuller, F. 1988. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331:525-527.
25. Quon, D., Wang, Y., Catalano, R., Scardina, J. M., Murakami, K., and Cordell, B. 1991. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352:239-241.
26. Higgins, L. S., Catalano, R., Quon, D., and Cordell, B. 1993. Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology. Ann. N. Y. Acad. Sci. 695:224-227.
27. Yamaguchi, F., Richards, S. J., Beyreuther, K., Salbaum, M., Carlson, G. A., and Dunnett, S. B. 1991. Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. Neuroreport 2:781-784.
28. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., Ledermann, B., Burki, K., Frey, P., Paganetti, P. A., Waridel, C., Calhoun, M. E., Jucker, M., Probst, A., Staufenbiel, M., and Sommer, B. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94:13287-13292.
29. Sommer, B., Sturchler-Pierrat, C., Abramowski, D., Wiederhold, K. H., Calhoun, M., Jucker, M., Kelly, P., and Staufenbiel, M. 2000. Transgenic approaches to model Alzheimer's disease. Rev. Neurosci. 11:47-51.
30. Nalbantoglu, J., Tirado-Santiago, G., Lahsaini, A., Poirier, J., Goncalves, O., Verge, G., Momoli, F., Welner, S. A., Massicotte, G., Julien, J. P., and Shapiro, M. L. 1997. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387:500-505.
31. Chishti, M. A., Yang, D. S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S., Morissette, C., Paquette, J., Gervais, F., Bergeron, C., Fraser, P. E., Carlson, G. A., George-Hyslop, P. S., and Westaway, D. 2001. Earlyonset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276:21562-21570.
32. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97-100.
33. Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., Yamaguchi, H., and Takashima, A. 2002. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22:133-141.
34. Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. V., Hope, C. E., Hatcher, J. M., DiCarlo, G., Gottschall, W. P., Morgan, D., and Arendash, G. W. 2001. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22:377-385.
35. Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., and Mucke, L. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96:3228-3233.
36. Dodart, J. C., Meziane, H., Mathis, C., Bales, K. R., Paul, S. M., and Ungerer, A. 1999. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci. 113:982-990.
37. King, D. L., Arendash, G. W., Crawford, F., Sterk, T., Menendez, J., and Mullan, M. J. 1999. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103:145-162.
38. Koistinaho, M., Ort, M., Cimadevilla, J. M., Vondrous, R., Cordell, B., Koistinaho, J., Bures, J., and Higgins, L. S. 2001. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98:14675-14680.
39. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., and Ashe, K. H. 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:1858-67.
40. Roher, A. E., Chaney, M. O., Kuo, Y. M., Webster, S. D., Stine, W. B., Haverkamp, L. J., Woods, A. S., Cotter, R. J., Tuohy, J. M., Krafft, G. A., Bonnell, B. S., and Emmerling, M. R. 1996. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271:20631-20635.
41. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. 1998. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95:6448-6453.
42. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:4050-4058.
43. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
44. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
45. Hartman, R. E., Wozniak, D. F., Nardi, A., Olney, J. W., Sartorius, L., and Holtzman, D. M. 2001. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 170:326-344.
46. Raber, J., Wong, D., Yu, G. Q., Buttini, M., Mahley, R. W., Pitas, R. E., and Mucke, L. 2000. Apolipoprotein E and cognitive performance. Nature 404:352-354.
47. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. 1999. Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400:173-177.
48. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
49. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St. George-Hyslop, P., and Westaway, D. 2000. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
50. Arendash, G. W., Gordon, M. N., Diamond, D. M., Austin, L. A., Hatcher, J. M., Jantzen, P., DiCarlo, G., Wilcock, D., and Morgan, D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell. Biol. 20:737-744.
51. Bliss, T. V. and Collingridge, G. L. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39.
52. Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V., Hyman, B. T., Younkin, S. G., and Hsiao, K. K. 1999. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:271-276.
53. Fitzjohn, S. M., Morton, R. A., Kuenzi, F., Rosahl, T. W., Shearman, M., Lewis, H., Smith, D., Reynolds, D. S., Davies, C. H., Collingridge, G. L., and Seabrook, G. R. 2001. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21:4691-4698.
54. Zucker, R. S. 1989. Short-term synaptic plasticity. Annu. Rev. Neurosci. 12:13-31.
55. Dewachter, I., van Dorpe, J., Spittaels, K., Tesseur, I., Van Den Haute, C., Moechars, D., and Van Leuven, F. 2000. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. 35:831-841.
56. Dewachter, I., Reverse, D., Caluwaerts, N., Ris, L., Kuiperi, C., Van den Haute, C., Spittaels, K., Umans, L., Serneels, L., Thiry, E., Moechars, D., Mercken, M., Godaux, E., and Van Leuven, F. 2002. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J. Neurosci. 22:3445-3453.